Publication | Open Access

Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice

NanomedicineDrug TargetingEnhanced Systemic ExposurePolymer-drug ConjugateMedicineSynergistic Therapeutic ResponseNano-drug DeliveryTumor TargetingTumour Growth SuppressionPharmacologyRadiation OncologyTumor MicroenvironmentTumor Biology